Semaglutide explained: tablets, injections and the evidence

What semaglutide is (and why you keep seeing “semaglitude”)

Let us clear up the spelling first, because it trips up a huge number of searches. If you have typed semaglitude into Google, you are looking for semaglutide — there is no separate medicine called “semaglitude.” It is one of the most common misspellings of the drug name in India, so you are in the right place.

Semaglutide is a GLP-1 receptor agonist. It mimics a natural gut hormone called glucagon-like peptide-1. In the body it stimulates glucose-dependent insulin secretion, suppresses glucagon and hepatic glucose production, delays how fast the stomach empties, and reduces appetite through pathways in the central nervous system. ^[5]

The phrase "receptor agonist" simply means the drug switches on the same receptor that your own GLP-1 hormone uses — it is a stand-in for a signal your body already makes, not a foreign stimulant. That is why its effects are described in terms of insulin, glucagon, stomach emptying and appetite rather than any single action. These are the pharmacology facts reported in the medical literature; they describe how the molecule behaves, not a guaranteed outcome for any person. ^[5]

What makes semaglutide practical as a medicine is its half-life of roughly one week — compared with just one to two minutes for the natural GLP-1 hormone. That long action comes from a modified molecular structure that resists breakdown by the DPP-4 enzyme and binds to albumin in the blood, which is what allows once-weekly injection. ^[5]

You will meet semaglutide under different brand names because it comes in more than one form. Oral semaglutide is sold as Rybelsus, a daily tablet approved for glycaemic control in type 2 diabetes. ^[6] The injectable forms are Ozempic, indicated for glycaemic control and cardiovascular risk reduction in type 2 diabetes, ^[8] and Wegovy, indicated for chronic weight management and cardiovascular risk reduction. ^[7] All of them are prescription-only. To understand the wider drug class this belongs to, see our complete guide to GLP-1 medicines.

What’s the difference between semaglutide tablets and injections?

The biggest source of confusion is that the tablet and the injection are the same molecule but were studied in different trial programmes, at different doses, for different goals. Understanding that is the key to reading any claim about semaglutide sensibly.

What did semaglutide’s clinical trials find?

Semaglutide’s trials measured different outcomes — weight, blood sugar and heart events — and here the numbers matter, so every figure below is attributed to its source trial. These are reported trial averages, not predictions for any individual — outcomes vary from person to person.

Weight (STEP 1). In the STEP 1 randomised trial of 1,961 adults with overweight or obesity over 68 weeks, semaglutide 2.4 mg injection once weekly produced a mean body-weight change of -14.9% versus -2.4% for placebo — a difference of 12.4 percentage points, or about -15.3 kg versus -2.6 kg. In that trial 86.4% reached at least 5% weight loss, 69.1% reached at least 10% and 50.5% reached at least 15%, compared with 31.5%, 12.0% and 4.9% on placebo. ^[1]

Blood sugar (PIONEER 1). In PIONEER 1, oral semaglutide 14 mg lowered HbA1c by 1.1% versus placebo at 26 weeks on the treatment-policy estimand, and by up to 1.4% on the trial-product estimand. ^[2] Across the PIONEER programme, the proportion of patients reaching an A1C below 7.0% was 42-69% on 7 mg and 55-77% on 14 mg, versus 7-31% on placebo. ^[4]

Heart outcomes (SUSTAIN-6 and SELECT). In SUSTAIN-6 (3,297 people, 104 weeks), once-weekly semaglutide cut the primary composite of cardiovascular death, non-fatal heart attack and non-fatal stroke by about 26% — 6.6% versus 8.9% on placebo (hazard ratio 0.74, 95% CI 0.58-0.95). ^[3] More recently, the SELECT trial (17,604 participants) supported the March 2024 US FDA approval of Wegovy for cardiovascular risk reduction, showing a 20% relative reduction in major cardiovascular events (6.5% vs 8.0%). ^[9]

Guideline view. The American Diabetes Association 2025 Standards of Care classify injectable semaglutide as a very-high-efficacy weight-loss agent and recommend a GLP-1 receptor agonist as preferred pharmacotherapy in type 2 diabetes with overweight or obesity; the guideline also cites STEP 2 data in people with diabetes. ^[14] For context on the scale of the problem these medicines are being studied for, the World Health Organization estimated that in 2022, 2.5 billion adults were overweight and 890 million were living with obesity. ^[10]

Semaglutide in India: which forms are actually available

India's semaglutide landscape changed fast in 2025-2026, so it is worth being precise about what is on the market.

Rybelsus (oral semaglutide) has been marketed in India by Novo Nordisk since 2022, in 3, 7 and 14 mg strengths. Its uptake has been steep: reported India sales grew from Rs 24 crore in April 2022 to Rs 147 crore in April 2023 and Rs 363 crore in April 2024. ^[13] On the injectable side, Wegovy launched in India in June 2025. ^[11]

The pivotal moment was the expiry of semaglutide's core Indian patent on 20 March 2026, which opened the market to generic manufacturers. ^[11]From 21 March 2026, multiple generic semaglutide products launched from companies including Dr Reddy's, Zydus (co-marketed by Lupin), Alkem, Sun Pharma and Glenmark. ^[12] One factual detail matters for anyone comparing tablets and injections: the verified 2026 generic launches were all injectable pens and vials — the reporting did not note a generic oral (Rybelsus-equivalent) tablet at launch. ^[12]

Availability is not the same as suitability. Whichever forms exist on the market, semaglutide remains a prescription-only medicine, and none of these launches changes the fact that a registered doctor decides whether and how it should be used. If your interest is weight, our guide to weight-loss injections in India explains how doctor-led programmes actually use these medicines.

What are the side effects of semaglutide?

The most common side effects of semaglutide are gastrointestinal, and nausea is the one people notice most. On the Wegovy 2.4 mg injection label, the most common adverse reactions (occurring in at least 5% of users) were nausea 44%, diarrhoea 30%, vomiting 24% and constipation 24%. ^[7] Those specific percentages are for the high-dose 2.4 mg injection, not the tablet.

For oral semaglutide, the Rybelsus label likewise reports gastrointestinal events as the most common adverse reactions, with nausea most common; the tablet's side-effect profile is described qualitatively here rather than with the injection's percentages. ^[6] In the PIONEER 1 trial, the most common adverse events with oral semaglutide were mild-to-moderate and transient gastrointestinal effects, which is the pattern the slow dose-escalation schedule is designed to soften. ^[2] That is why the tablet starts at a sub-therapeutic 3 mg and the injection is titrated over weeks rather than started at full dose.

Even so, side effects are a real reason people stop treatment. In STEP 1, 4.5% of people discontinued semaglutide for gastrointestinal events, versus 0.8% on placebo — a reminder that tolerability, not just efficacy, shapes whether a medicine is right for someone. ^[1] Managing that trade-off is a job for a prescriber who can adjust the dose, pause escalation or stop the drug.

More seriously, all semaglutide products carry a boxed warning for thyroid C-cell tumours (medullary thyroid carcinoma) based on rodent studies, and are contraindicated in people with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). ^{[6] [7] [8]} This is exactly the kind of contraindication that a doctor screens for before prescribing — and that you cannot safely screen for yourself.

How does semaglutide compare with tirzepatide?

Semaglutide and tirzepatide (brand name Mounjaro) are the GLP-1-family medicines people most often compare, and they are related but not identical: semaglutide is a GLP-1 receptor agonist, while tirzepatide is a dual GIP and GLP-1 receptor agonist. The ADA 2025 Standards of Care classify both as very-high-efficacy weight-loss agents. ^[14]The table below compares only what the verified evidence in this article supports; for tirzepatide's own trial numbers, see our dedicated guide.

A comparison table is a starting point, not a verdict. The right medicine, if any, depends on your diagnosis, other conditions, tolerance of side effects and monitoring — which is a clinical judgment. Read the full picture in our Mounjaro (tirzepatide) guide before drawing conclusions.

Why medical supervision is non-negotiable

Everything above points to the same conclusion. Semaglutide is a powerful, prescription-only medicine with a boxed safety warning, strict contraindications, a careful dose-escalation schedule and — for the tablet — an absorption rule that changes how much drug you even receive. ^{[6] [7]} None of that can be managed safely by a website, a pharmacy shelf or a social-media post.

The trial results are genuinely striking, but they were produced under medical supervision, with monitoring, dose titration and screening for the people who should never take the drug. That supervision is part of the result — not an optional extra. At MensMD, no treatment is ever decided by our platform; whether semaglutide or any other medicine is appropriate for you is decided solely by a registered medical practitioner after assessing your health.

The wave of new brands and generics arriving in India makes supervision more important, not less. When a medicine is suddenly easier to obtain, the temptation to self-prescribe rises — but the boxed warning, the contraindications and the dose schedule do not change just because supply expands. A registered doctor is the person who checks whether you have a condition that rules the drug out, chooses the right formulation and dose, monitors your response and manages side effects over time. That ongoing relationship is the safeguard, and no amount of market availability replaces it.

If weight is your concern, the sensible first step is a proper assessment rather than a purchase. You can learn how a doctor-led pathway works through our weight-loss program, which starts with evaluation, not a prescription.

Frequently asked questions